Increasing negative lymph node count predicts favorable OS and DSS in breast cancer with different lymph node-positive subgroups

Xin Zhao\(^1\), Jing Wei\(^2\), Xiaoxin Li\(^3\), Haochang Yang\(^4\), Pei Wang\(^5\)*, Susheng Cao\(^5\)*

\(^1\) Department of General Surgery, Tianjin First Central Hospital, Tianjin, China, \(^2\) Department of Thoracic Surgery, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, China, \(^3\) Department of Pathology, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, China, \(^4\) College of Clinical Medicine, Binzhou Medical University, Yantai, China, \(^5\) Department of Breast Surgery, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, China

* These authors contributed equally to this work.

\* cssxzsy@126.com (SC); 13495333289@qq.com (PW)

Abstract

Adequate lymph node evaluation is recommended for optimal staging in patients with malignant neoplasms including breast cancer. However, the role of negative lymph nodes (LNs) remains unclear in breast cancer according to N substage (N1, N2, and N3). In this study, for the first time, we analyzed the prognostic significance of negative LNs in breast cancer patients. A critical relationship was observed between negative LN count and survival, independent of patient characteristics and other related molecular variables including estrogen receptor (PR) status, progesterone receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, depth of tumor invasion and degree of differentiation. This research is of great importance in providing more information about the prognosis of breast cancer by statistical analysis of negative lymph nodes and can serve as a useful supplement to the current pathological system.

Introduction

Breast cancer is one of the most common carcinomas worldwide, especially among females [1]. The prognosis of patients with early stage breast cancer is favorable, but patients with lymph node (LN) metastasis usually have a poor prognosis; the more metastatic lymph nodes identified, the worse the long-term survival [2]. In the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC) tumor-node-metastasis (TNM) classification [3], positive LNs are classified into 3 subgroups: N1 (1–3 LNs), N2 (4–9 LNs) and N3 (10 or more LNs). The staging system can discriminate prognostic groups very well. However, it is difficult to correctly assess a patient’s TNM classification. For example, one of the classic questions is the minimum number of LNs that should be dissected. Unfortunately, the number reported in the literature is inconsistent, ranging from 5 to 15 [4–8].
In addition to the total number of LNs excised, many other parameters have been developed and validated for various malignancies, such as number of negative lymph nodes [9,10], ratio of involved to removed nodes (lymph node ratio, LNR) [11,12], and log odds of positive lymph nodes (LODDS) [13,14], to aid the TNM system in predicting the outcome more accurately. However, few studies have focused on the relationship between the number of negative LNs and prognosis of breast cancer. Kuru [9] compared the roles of total number of nodes removed, negative nodes removed, and ratio of positive nodes to removed nodes in breast cancer using small samples from a single institute. Vinh-Hung et al [15] investigated the effect of number of negative nodes on survival in early breast cancer using the Surveillance Epidemiology and End Results (SEER) database. To the best of our knowledge, this study is the first to evaluate the role of negative LN count in breast cancer according to N substage (N1, N2, and N3) using a population-based database.

Materials and methods

Patients

Patients were collected from the SEER database (2004–2013), which is a population-based cancer registry in the United States. The National Cancer Institute’s SEER Stat software (Version 8.2.0) was applied to identify patients with breast cancer. Included in the study were patients more than 18 years old, who had received surgical treatment and a pathologically confirmed diagnosis of breast cancer. The exclusion criteria were as follows: (1) patients for whom the number of examined or positive regional lymph nodes was 0 or unknown; (2) patients with distant metastasis (M1); (3) patients with a history of prior malignancy; and (4) patients with chemotherapy or radiotherapy before surgery. We retrieved baseline and clinical characteristics, including sex, age, race, tumor grade, T stage according to the 6th and 7th edition of AJCC criteria, estrogen receptor (ER) status, progesterone receptor (PR) status and human epidermal growth factor receptor 2 (HER2) status. All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by the Bioethics Committee of the Affiliated XuZhou Hospital of Medical College of Southeast University, China. Informed consent was obtained from all subjects in the SEER database.

Statistical analysis

Data about baseline and clinical characteristics were presented as count and percent values. The selection of the subgroups in the negative number of lymph nodes was determined by X-tile software (Yale University, Version 3.6.1). Overall survival (OS) and disease-specific survival (DSS) were evaluated by the Kaplan-Meier method. OS was calculated from the time of initial diagnosis to last follow-up or death, and DSS was defined as the interval from diagnosis until death due to breast cancer. Multivariate analyses for OS and DSS of breast cancer were performed by Cox regression models with adjusted hazard ratios (HRs). P values < 0.05 were considered statistically significant. All analyses were conducted utilizing PASW Statistics 18 software.

Results

A total of 125981 patients with breast cancer and positive LNs were selected from the SEER database, including 87523 cases with N1 substage, 26350 cases with N2 substage, and 12108 cases with N3 substage. Baseline and clinical characteristics are shown in Table 1. Most patients were female (99.1%), and the median age was 56 years old. The majority of patients...
had early T stage (T1 accounting for 37.7%, T2 accounting for 44.7%). The number of negative LNs for the cohort ranged from 0 to 77, and the median number was 8.

During the follow-up period, 21679 (17.2%) patients in the entire cohort died. Overall, 14729 patients died from breast cancer, accounting for 67.9% (14729/21679) of total deaths. Taking into consideration the optimal cutoff number of negative LNs acquired by X-tile software in N1, N2 and N3 substage and the number of negative LNs in each subgroup, four negative LNs were categorized as an interval. The N1, N2 and N3 substage were divided into 4 subgroups: 0–3, 4–7, 8–11 and more than 11. OS and DSS for N1, N2 and N3 substage

| Characteristics | All patients (n = 125981) | N1 Substage (n = 87523) | N2 Substage (n = 26350) | N3 Substage (n = 12108) | P |
|-----------------|---------------------------|------------------------|------------------------|------------------------|---|
| Age, years      |                           |                        |                        |                        |   |
| Median          | 56                        | 56                     | 56                     | 57                     | <0.001 |
| Sex             |                           |                        |                        |                        | 0.425 |
| Female          | 124813 (99.1%)            | 86732 (99.1%)          | 26091 (99.0%)          | 11990 (99.0%)          |   |
| Male            | 1168 (0.9%)               | 791 (0.9%)             | 259 (1.0%)             | 118 (1.0%)             |   |
| Race            |                           |                        |                        |                        | <0.001 |
| White           | 99520 (79.0%)             | 69426 (79.3%)          | 20537 (77.9%)          | 9557 (78.9%)           |   |
| Black           | 15258 (12.1%)             | 10151 (11.6%)          | 3531 (13.4%)           | 1576 (13.0%)           |   |
| Others          | 11203 (8.9%)              | 7946 (9.1%)            | 2282 (8.7%)            | 975 (8.1%)             |   |
| Grade*          |                           |                        |                        |                        |   |
| Well or moderately differentiated | 67652 (53.7%) | 50022 (57.2%) | 12600 (47.8%) | 5030 (41.5%) | <0.001 |
| Poorly differentiated or undifferentiated | 53470 (42.4%) | 34228 (39.1%) | 12719 (48.2%) | 6523 (53.9%) |   |
| T stage**       |                           |                        |                        |                        | <0.001 |
| T1              | 47554 (37.7%)             | 39430 (45.1%)          | 6190 (23.5%)           | 1934 (16.0%)           |   |
| T2              | 56336 (44.7%)             | 37847 (43.2%)          | 13055 (49.5%)          | 5434 (44.9%)           |   |
| T3              | 13385 (10.6%)             | 6329 (7.2%)            | 4224 (16.0%)           | 2832 (23.4%)           |   |
| T4              | 6831 (5.4%)               | 2702 (3.1%)            | 2447 (9.3%)            | 1682 (13.9%)           |   |
| ER status       |                           |                        |                        |                        | <0.001 |
| Positive        | 96859 (76.9%)             | 68583 (78.4%)          | 19679 (74.7%)          | 8597 (71.0%)           |   |
| Negative        | 25014 (19.9%)             | 16120 (18.4%)          | 5777 (21.9%)           | 3117 (25.7%)           |   |
| Others          | 4108 (3.2%)               | 2820 (3.2%)            | 894 (3.4%)             | 394 (3.3%)             |   |
| PR status       |                           |                        |                        |                        | <0.001 |
| Positive        | 82663 (65.6%)             | 59181 (67.6%)          | 16510 (62.7%)          | 6972 (57.6%)           |   |
| Negative        | 38120 (30.3%)             | 24789 (28.3%)          | 8707 (33.0%)           | 4624 (38.2%)           |   |
| Others          | 5198 (4.1%)               | 3553 (4.1%)            | 1133 (4.3%)            | 512 (4.2%)             |   |
| HER2 status     |                           |                        |                        |                        | <0.001 |
| Positive        | 80436 (6.4%)              | 54736 (6.3%)           | 17356 (6.6%)           | 8356 (6.9%)            |   |
| Negative        | 38959 (30.9%)             | 28146 (32.2%)          | 7436 (28.2%)           | 3377 (27.9%)           |   |
| Others          | 78979 (62.7%)             | 53904 (61.6%)          | 17179 (65.2%)          | 7896 (65.2%)           |   |
| NO. of negative LNs |                      |                        |                        |                        | <0.001 |
| 0–3             | 33826 (26.9%)             | 22409 (25.6%)          | 5402 (20.5%)           | 6015 (49.7%)           |   |
| 4–7             | 25315 (20.1%)             | 15520 (17.7%)          | 6724 (25.3%)           | 3071 (25.4%)           |   |
| 8–11            | 25037 (19.9%)             | 17404 (19.9%)          | 6092 (23.1%)           | 1541 (12.7%)           |   |
| >11             | 41803 (33.2%)             | 32190 (36.8%)          | 8132 (30.9%)           | 1481 (12.2%)           |   |

*Grade information missing for 4859 patients (3.9%).
**T stage information missing for 590 patients (0.5%).
ER = estrogen receptor, PR = progesterone receptor, HER2 = human epidermal growth factor receptor 2.

https://doi.org/10.1371/journal.pone.0193784.t001
stratified by 4 subgroups are presented in Fig 1A, 1B, 1C, 1D, 1E and 1F. For all three N sub-stages, the differences in both OS and DSS were statistically significant ($P < 0.001$). It should be noted that there was no difference between N1 patients with 4–7 negative LNs and those...
with 8–11 for OS ($P > 0.05$). No significant differences were observed among N1 patients with subgroups 4–7, 8–11 and more than 11 for DSS ($P > 0.05$). All the survival curves indicated that patients with more negative LNs had better outcomes, especially for N2 and N3 substage.

The effect of negative LNs on prognosis was evaluated by multivariate analyses (Tables 2 and 3). The number of negative LNs was an independent prognostic factor for OS and CSS in each N substage. A larger number of negative LNs had a more positive effect on the prognosis.

### Table 2. Multivariate analyses for OS in breast cancer patients with positive lymph nodes.

| Characteristics          | N1 Substage (n = 87523) | N2 Substage (n = 26350) | N3 Substage (n = 12108) |
|--------------------------|-------------------------|-------------------------|-------------------------|
|                          | HR 95% CI P             | HR 95% CI P             | HR 95% CI P             |
| **Age, years**           |                         |                         |                         |
| ≤55                      | 1.0 Reference           | 1.0 Reference           | 1.0 Reference           |
| >55                      | 2.414 2.315–2.518 <0.001| 1.765 1.672–1.862 <0.001| 1.493 1.401–1.592 <0.001|
| **Sex**                  |                         |                         |                         |
| Male                     | 1.0 Reference           | 1.0 Reference           | 1.0 Reference           |
| Female                   | 0.560 0.478–0.656 <0.001| 0.693 0.549–0.876 0.002 | 0.860 0.629–1.177 0.347 |
| **Race**                 |                         |                         |                         |
| White                    | 1.0 Reference           | 1.0 Reference           | 1.0 Reference           |
| Black                    | 1.348 1.279–1.422 <0.001| 1.499 1.402–1.603 <0.001| 1.481 1.362–1.611 <0.001|
| Others                   | 0.755 0.697–0.818 <0.001| 0.806 0.724–0.898 <0.001| 0.752 0.660–0.856 <0.001|
| **Grade**                |                         |                         |                         |
| Well or moderately differentiated | 1.0 Reference | 1.0 Reference | 1.0 Reference |
| Poorly differentiated or undifferentiated | 1.407 1.348–1.470 <0.001 | 1.408 1.329–1.491 <0.001 | 1.434 1.336–1.540 <0.001 |
| **T stage**              |                         |                         |                         |
| T1                       | 1.0 Reference           | 1.0 Reference           | 1.0 Reference           |
| T2                       | 1.821 1.743–1.903 <0.001| 1.524 1.415–1.641 <0.001| 1.455 1.312–1.613 <0.001|
| T3                       | 2.506 2.338–2.687 <0.001| 2.060 1.886–2.250 <0.001| 1.872 1.675–2.092 <0.001|
| T4                       | 3.995 3.700–4.313 <0.001| 2.606 2.379–2.856 <0.001| 2.629 2.348–2.944 <0.001|
| **ER status**            |                         |                         |                         |
| Positive                 | 1.0 Reference           | 1.0 Reference           | 1.0 Reference           |
| Negative                 | 1.422 1.338–1.511 <0.001| 1.507 1.391–1.632 <0.001| 1.412 1.289–1.548 <0.001|
| Others                   | 1.265 1.060–1.510 0.009 | 1.308 1.018–1.680 0.035 | 1.502 1.132–1.992 0.005 |
| **PR status**            |                         |                         |                         |
| Positive                 | 1.0 Reference           | 1.0 Reference           | 1.0 Reference           |
| Negative                 | 1.338 1.265–1.415 <0.001| 1.404 1.302–1.515 <0.001| 1.460 1.337–1.593 <0.001|
| Others                   | 1.183 1.007–1.390 0.041 | 1.161 0.924–1.459 0.200 | 1.209 0.932–1.567 0.153 |
| **HER2 status**          |                         |                         |                         |
| Positive                 | 1.0 Reference           | 1.0 Reference           | 1.0 Reference           |
| Negative                 | 1.552 1.328–1.813 <0.001| 1.342 1.110–1.622 0.002 | 1.636 1.313–2.038 <0.001|
| Others                   | 1.620 1.398–1.878 <0.001| 1.297 1.088–1.547 0.004 | 1.487 2.211–1.827 <0.001|
| **NO. of negative LNs**  |                         |                         |                         |
| 0–3                      | 1.0 Reference           | 1.0 Reference           | 1.0 Reference           |
| 4–7                      | 0.823 0.776–0.871 <0.001| 0.686 0.640–0.735 <0.001| 0.741 0.686–0.801 <0.001|
| 8–11                     | 0.786 0.744–0.831 <0.001| 0.589 0.547–0.634 <0.001| 0.647 0.582–0.719 <0.001|
| >11                      | 0.636 0.605–0.670 <0.001| 0.489 0.455–0.526 <0.001| 0.536 0.478–0.601 <0.001|

*Grade information missing for 4859 patients (3.9%).
**T stage information missing for 590 patients (0.5%).

https://doi.org/10.1371/journal.pone.0193784.t002
of breast cancer. N2 disease was most influenced; patients with more than 11 negative LNs compared with patients with 0–3 negative LNs had 48.9% of the death risk for OS (95% CI, 0.455 to 0.526, respectively) and 43.9% for DSS (95% CI, 0.403 to 0.478, respectively). Additionally, T stage, ER status (positive vs. negative), PR status (positive vs. negative), HER2 status (positive vs. negative), grade (well or moderately differentiated vs. poorly differentiated or undifferentiated), age (≤55 years vs. >55 years) and race (white vs. black) were independent prognostic factors for all patients. Sex did not always influence mortality independently.

| Characteristics | N1 Substage (n = 87523) | N2 Substage (n = 26350) | N3 Substage (n = 12108) |
|-----------------|-------------------------|-------------------------|-------------------------|
|                 | HR          | 95% CI    | P   | HR          | 95% CI    | P   | HR          | 95% CI    | P   |
| Age, years      |             |           |     |             |           |     |             |           |     |
| ≤55             | 1.0         | Reference | 1.0 | Reference   | 1.0       | Reference | 1.0 | Reference   | 1.0       | Reference |
| >55             | 1.462       | 1.389–1.538 | <0.001 | 1.297 | 1.220–1.378 | <0.001 | 1.230 | 1.147–1.319 | <0.001 |
| Sex             |             |           |     |             |           |     |             |           |     |
| Male            | 1.0         | Reference | 1.0 | Reference   | 1.0       | Reference | 1.0 | Reference   | 1.0       | Reference |
| Female          | 0.688       | 0.535–0.885 | 0.004 | 0.889 | 0.643–1.231 | 0.479 | 0.875 | 0.606–1.265 | 0.477 |
| Race            |             |           |     |             |           |     |             |           |     |
| White           | 1.0         | Reference | 1.0 | Reference   | 1.0       | Reference | 1.0 | Reference   | 1.0       | Reference |
| Black           | 1.332       | 1.246–1.423 | <0.001 | 1.492 | 1.381–1.61 | <0.001 | 1.431 | 1.304–1.570 | <0.001 |
| Others          | 0.757       | 0.684–0.838 | <0.001 | 0.850 | 0.753–0.959 | 0.008 | 0.751 | 0.651–0.866 | <0.001 |
| Grade*          |             |           |     |             |           |     |             |           |     |
| Well or moderately differentiated | 1.0 | Reference | 1.0 | Reference   | 1.0       | Reference | 1.0 | Reference   | 1.0       | Reference |
| Poorly differentiated or undifferentiated | 1.874 | 1.767–1.988 | <0.001 | 1.550 | 1.447–1.660 | <0.001 | 1.515 | 1.398–1.642 | <0.001 |
| T stage**       |             |           |     |             |           |     |             |           |     |
| T1              | 1.0         | Reference | 1.0 | Reference   | 1.0       | Reference | 1.0 | Reference   | 1.0       | Reference |
| T2              | 2.144       | 2.017–2.280 | <0.001 | 1.636 | 1.495–1.789 | <0.001 | 1.430 | 1.275–1.603 | <0.001 |
| T3              | 3.386       | 3.105–3.692 | <0.001 | 2.339 | 2.108–2.595 | <0.001 | 1.908 | 1.687–2.678 | <0.001 |
| T4              | 5.418       | 4.927–5.958 | <0.001 | 2.953 | 2.651–3.288 | <0.001 | 2.632 | 2.322–2.982 | <0.001 |
| ER status       |             |           |     |             |           |     |             |           |     |
| Positive        | 1.0         | Reference | 1.0 | Reference   | 1.0       | Reference | 1.0 | Reference   | 1.0       | Reference |
| Negative        | 1.572       | 1.457–1.695 | <0.001 | 1.662 | 1.517–1.822 | <0.001 | 1.449 | 1.311–1.602 | <0.001 |
| Others          | 1.156       | 0.909–1.470 | 0.236 | 1.493 | 1.097–2.032 | 0.011 | 1.489 | 1.091–2.031 | 0.012 |
| PR status       |             |           |     |             |           |     |             |           |     |
| Positive        | 1.0         | Reference | 1.0 | Reference   | 1.0       | Reference | 1.0 | Reference   | 1.0       | Reference |
| Negative        | 1.614       | 1.499–1.738 | <0.001 | 1.523 | 1.392–1.665 | <0.001 | 1.601 | 1.453–1.765 | <0.001 |
| Others          | 1.348       | 1.084–1.678 | 0.007 | 1.077 | 0.810–1.433 | 0.608 | 1.346 | 1.012–1.790 | 0.041 |
| HER2 status     |             |           |     |             |           |     |             |           |     |
| Positive        | 1.0         | Reference | 1.0 | Reference   | 1.0       | Reference | 1.0 | Reference   | 1.0       | Reference |
| Negative        | 1.785       | 1.464–2.175 | <0.001 | 1.470 | 1.185–1.824 | <0.001 | 1.785 | 1.395–2.283 | <0.001 |
| Others          | 1.772       | 1.469–2.136 | <0.001 | 1.313 | 1.074–1.604 | 0.008 | 1.591 | 1.263–2.003 | <0.001 |
| NO. of negative LNs |         |           |     |             |           |     |             |           |     |
| 0–3             | 1.0         | Reference | 1.0 | Reference   | 1.0       | Reference | 1.0 | Reference   | 1.0       | Reference |
| 4–7             | 0.810       | 0.751–0.875 | <0.001 | 0.661 | 0.610–0.715 | <0.001 | 0.715 | 0.656–0.778 | <0.001 |
| 8–11            | 0.799       | 0.743–0.859 | <0.001 | 0.557 | 0.511–0.607 | <0.001 | 0.616 | 0.548–0.693 | <0.001 |
| >11             | 0.630       | 0.589–0.673 | <0.001 | 0.439 | 0.403–0.478 | <0.001 | 0.511 | 0.450–0.581 | <0.001 |

*Grade information missing for 4859 patients (3.9%).
**T stage information missing for 590 patients (0.5%).

https://doi.org/10.1371/journal.pone.0193784.t003
For example, sex had no effect on either OS or DSS for N3 substage ($P = 0.360$, $P = 0.495$, respectively).

**Discussion**

The TNM classification system attempts to account for most basic parameters of cancer, to provide guidance for treatment planning and to predict the outcome. The number of positive LNs has been the focus on for a long time. In the present study, for the first time, we analyzed the prognostic significance of negative LNs in breast cancer patients. We observed a critical relationship between negative lymph node count and survival, independent of patient characteristics and other related molecular variables including PR status, ER status, HER2 status, depth of tumor invasion and degree of differentiation.

Although the number of negative LNs has an apparent effect on survival in each N stage, the mechanism underlying the relationship between negative LNs and survival remains unconfirmed. It has been reported that stage migration probably occurs due to under-evaluation of total lymph nodes, which has an intimate connection with the number of positive and negative LNs, thus influencing on pathological stage. Examining more lymph nodes can more accurately identify metastasis, thus avoiding misclassification of pathological stage [16].

Another possible hypothesis is that the number of negative LNs reflects the host lymphocytic reaction to tumor. The interaction between host and tumor contributes to the size or count of lymph nodes, and the increase of negative LNs indicates that the host takes a predominant position when competing with a tumor, and consequently obtains longer survival. A similar hypothesis has been associated with longer survival in colorectal cancer [17,18].

The number of lymph nodes informs the surgical approach, classification of pathological stage and institutional care. It has been reported that the number of lymph nodes may have a connection with better care overall and may not affect outcome directly [19–22]. There are also studies showing that the removal of more lymph nodes leads to a better prognosis [11]. Negative lymph nodes, clinically, imply that cancer cells were not observed using microscopy, instead of absolute no-tumor-metastasis, which means that there may be micro-metastasis of cancer cells. In other words, positive lymph nodes examined on routine pathological analysis do not necessarily reflect lymph node metastasis. For approximately 9%-30% of breast cancer patients, there are micro-metastases in their axillary lymph nodes that are undetectable by routine pathological examination [23]. Lymph node micro-metastasis is a strong risk factor for tumor-free survival and metastatic recurrence [24]. Therefore, the increase of the negative lymph node count, to a certain extent, can avoid the adverse effects of lymph node micro-metastasis and improve the prognosis of patients [25,26].

The rate of LNR was not used in this study to assess the prognosis of patients. LNR refers to the ratio of the number of metastatic lymph nodes to the total number of lymph nodes cleared. In recent years, many studies have indicated that LNR is superior to pN staging in reflecting axillary lymph node status and predicting prognosis [11, 27–31]. pN staging depends on the number of positive lymph nodes and the total number of lymph nodes cleared. Different from pN staging, LNR balances the potential influencing factors. It can better reflect axillary lymph node stage, as well as prognosis [32,33]. In a meta-analysis study, Woodward also suggested that LNR is better as a prognostic index than the number of metastatic lymph nodes [34].

In addition, we only selected patients from the SEER database to analyze survival and prognostic factors. It is necessary for us to obtain more detailed information to confirm the relationship between negative LNs and survival.

In conclusion, we confirmed, for the first time, the relationship between negative lymph node count and prognosis of breast cancer in substage N2 and N3. The analysis is consistent
with the presentation of colorectal cancer: more negative LNs imply longer survival [35–38]. It is of great importance to provide more information about the prognosis of breast cancer by statistical analysis of negative lymph nodes, which can serve as a useful supplement to the current pathological system.

Supporting information
S1 File. Detailed data of all the patients from SEER.
(XLSX)

Author Contributions
Conceptualization: Pei Wang, Susheng Cao.
Data curation: Xin Zhao, Susheng Cao.
Formal analysis: Xin Zhao, Jing Wei, Susheng Cao.
Investigation: Xin Zhao, Jing Wei, Haochang Yang, Susheng Cao.
Methodology: Jing Wei, Haochang Yang, Susheng Cao.
Project administration: Pei Wang, Susheng Cao.
Resources: Susheng Cao.
Software: Xin Zhao, Xiaoxin Li, Haochang Yang, Susheng Cao.
Supervision: Xiaoxin Li, Pei Wang, Susheng Cao.
Validation: Xin Zhao, Xiaoxin Li, Pei Wang, Susheng Cao.
Writing – original draft: Xin Zhao, Jing Wei.
Writing – review & editing: Pei Wang, Susheng Cao.

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87–108. https://doi.org/10.3322/caac.21262 PMID: 25651787
2. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, et al: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983; 52: 1551–1557. PMID: 6352003
3. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17: 1471–1474. https://doi.org/10.1245/s10434-010-0985-4 PMID: 20180029
4. Rosen PP, Lesser ML, Kinne DW, Beattie EJ. Discontinuous or “skip” metastases in breast carcinoma. Analysis of 1228 axillary dissections. Ann Surg. 1983; 197: 276–283. PMID: 6830335
5. van Lancker M, Goor C, Sacre R, Lamote J, Van Belle S, De Coene N, et al. Patterns of axillary lymph node metastasis in breast cancer. Am J Clin Oncol. 1995; 18: 267–272. PMID: 7747717
6. Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBC) G. Eur J Cancer. 1992; 28: 1415–1418.
7. Gravesen HP, Blichert-Toft M, Andersen JA, Zedeler K. Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol. 1988; 14: 407–412. PMID: 3161444
8. Somner JE, Dixon JM, Thomas JS. Node retrieval in axillary lymph node dissections: recommendations for minimum numbers to be confident about node negative status. J Clin Pathol. 2004; 57: 845–848. https://doi.org/10.1136/jcp.2003.015560 PMID: 15280406
9. Kuru B. Prognostic significance of total number of nodes removed, negative nodes removed, and ratio of positive nodes to removed nodes in node positive breast carcinoma. Eur J Surg Oncol. 2006; 32: 1082–1088. https://doi.org/10.1016/j.ejso.2006.06.005 PMID: 16887320

10. Karlsson P, Cole BF, Price KN, Coates AS, Castiglione-Gertsch M, Gusterson BA, et al. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. J Clin Oncol. 2007; 25: 2019–2026. https://doi.org/10.1200/JCO.2006.09.8152 PMID: 17420511

11. Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, et al. Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Ann Surg Oncol. 2012; 19: 1808–1817. https://doi.org/10.1245/s10434-011-2189-y PMID: 22207051

12. Vinh-Hung V, Verschraegen C, Promish DI, Cserni G, Van de Steene J, Tai P, et al. Ratios of involved nodes in early breast cancer. Breast Cancer Res. 2004; 6: 680–688. https://doi.org/10.1186/bcr934 PMID: 15535850

13. La Torre M, Nigri G, Petrucciani N, Cavallini M, Aurello P, Cosenza G, et al. Prognostic assessment of different lymph node staging methods for pancreatic cancer with R0 resection: pN staging, lymph node ratio, log odds of positive lymph nodes. Pancreatology. 2014; 14: 289–294. https://doi.org/10.1016/j.pan.2014.05.0.794 PMID: 25062879

14. Arslan NC, Sokmen S, Canda AE, Terzi C, Sarioglu S. The prognostic impact of the log odds of positive lymph nodes in colon cancer. Colorectal Dis. 2014; 16: 386–392. https://doi.org/10.1111/codi.12702 PMID: 24980876

15. Vinh-Hung V, Cserni G, Burzykowski T, van de Steene J, Voordekkers M, Storme G. Effect of the number of uninvolved nodes on survival in early breast cancer. Oncol Rep. 2003; 10: 363–368. PMID: 12579273

16. Aurello P, D’Angelo F, Rossi S, Bellagamba R, Cicchini C, Nigri G, et al. Classification of lymph node metastases from gastric cancer: comparison between N-site and N-number systems. Our experience and review of the literature. Am Surg. 2007; 73: 359–366. PMID: 17439029

17. Pagès F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol. 2008; 84: 981–987. https://doi.org/10.1189/jlb.1107773 PMID: 18559950

18. Morris M, Platec I, Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res. 2006; 12: 1413–1417. https://doi.org/10.1158/1078-0432.CCR-06-0569 PMID: 17121888

19. Schrag D, Panageas KS, Riedel E, Hsieh L, Bach PB, Guillem JG, et al. Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. J Surg Oncol. 2003; 83: 68–78. https://doi.org/10.1002/jso.10244 PMID: 12772198

20. Kaiser AM, Nunoo-Mensah JW, Wasserberg N. Re: Surgical volume and long-term survival following surgery for colorectal cancer in the Veterans Affairs Health-Care System. Am J Gastroenterol. 2005; 100: 250. https://doi.org/10.1111/j.1572-0241.2005.41277_5.x PMID: 15654811

21. Aslam MI, Venkatesh J, Jameson JS, West K, Pringle JH, Singh B. Identification of high-risk Dukes B colorectal cancer by microRNA expression profiling: a preliminary study. Colorectal Dis. 2015; 17: 578–588. https://doi.org/10.1111/codi.12886 PMID: 25557290

22. Goldstein NS. Lymph node recoveries from 2427 pT3 colorectal resection specimens spanning 45 years: recommendations for a minimum number of recovered lymph nodes based on predictive probabilities. Am J Surg Pathol. 2002; 26: 179–189. PMID: 11812939

23. Al-Shibli KI, Mohammed HA, Mikalsen KS. Sentinel lymph nodes and breast carcinoma: analysis of 70 cases by frozen section. Ann Saudi Med. 2005; 25: 111–114. PMID: 15977687

24. Querzoli P, Pedriali M, Rinaldi R, Lombardi AR, Biganzoli E, Boracchi P et al. Axillary lymph node micrometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. J Cancer Res. 2006; 12: 6696–6701. https://doi.org/10.1158/1078-0432.CCR-06-0569 PMID: 17121888

25. Gyorki DE, Henderson MA. Significance of sentinel lymph node micrometastases in patients with breast cancer. J Clin Oncol. 2010; 28: e139. https://doi.org/10.1200/JCO.2009.26.1420 PMID: 20159811

26. de Boer M, van Deurzen CH, van Dieck JA, Borm GF, van Diest PJ, Adang EM, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009; 361: 653–663. https://doi.org/10.1056/NEJMoa0904832 PMID: 19675329

27. Dings PJ, Elferink MA, Strobbe LJ, de Wilt JH. The prognostic value of lymph node ratio in node-positive breast cancer: a Dutch nationwide population-based study. Ann Surg Oncol. 2013; 20: 2607–2614. https://doi.org/10.1245/s10434-013-2932-7 PMID: 23560553

28. Schiffman SC, McMasters KM, Scoggins CR, Martin RC, Chagpar AB. Lymph node ratio: a proposed refinement of current axillary staging in breast cancer patients. J Am Coll Surg. 2011; 213:45–52. https://doi.org/10.1016/j.jamcollsurg.2011.04.024 PMID: 21601490
29. Vinh-Hung V, Verkooijen HM, Fioretta G, Neyroud-Casper I, Rapiti E, Vlastos G, et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol. 2009; 27: 1062–1068. https://doi.org/10.1200/JCO.2008.18.6965 PMID: 19164210

30. Vinh-Hung V, Nguyen NP, Cserni G, Truong P, Woodward W, Verkooijen HM, et al. Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. Future Oncol. 2009; 5: 1585–1603. https://doi.org/10.2217/lon.09.129 PMID: 20001797

31. Voordeekers M, Vinh-Hung V, Van de Steene J, Lamote J, Storme G. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol. 2004; 70: 225–230. https://doi.org/10.1016/j.radonc.2003.10.015 PMID: 15064006

32. Martin FT, O'Fearraigh C, Hanley C, Curran C, Sweeney KJ, Kerin MJ. The prognostic significance of nodal ratio on breast cancer recurrence and its potential for incorporation in a new prognostic index. Breast J. 2013; 19: 388–393. https://doi.org/10.1111/tbj.12122 PMID: 23721403

33. Ahn SH, Kim HJ, Lee JW, Gong GY, Noh DY, Yang JH, et al. Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society. Breast Cancer Res Treat, 2011; 130: 507–515. https://doi.org/10.1007/s10549-011-1730-9 PMID: 21858659

34. Woodward WA, Vinh-Hung V, Ueno NT, Cheng YC, Royce M, Tai P, et al. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol. 2006; 24: 2910–2916. https://doi.org/10.1200/JCO.2005.03.1526 PMID: 16782931

35. Jestin P, Påhlman L, Glimelius B, Gunnarsson U. Cancer staging and survival in colon cancer is dependent on the quality of the pathologists’ specimen examination. Eur J Cancer. 2005; 41: 2071–2078. https://doi.org/10.1016/j.ejca.2005.06.012 PMID: 16125926

36. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007; 99: 433–441. https://doi.org/10.1093/jnci/djk092 PMID: 17374833

37. George S, Primrose J, Talbot R, Smith J, Mullee M, Bailey D, et al. Wessex Colorectal Cancer Audit Working Group. Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists. Br J Cancer. 2006; 95: 841–847. https://doi.org/10.1038/sj.bjc.6603352 PMID: 16969342

38. Iachetta F, Reggiani Bonetti L, Marcheselli L, Di Gregorio C, Cirilli C, Messinesse S, et al. Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: a population-based study. Acta Oncol. 2013; 52: 1682–1690. https://doi.org/10.3109/0284186X.2013.808376 PMID: 23786176